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Background: Nonsense-Mediated decay (NMD) selectively degrades mRNA transcripts that carry premature stop
codons. NMD is often triggered by alternative splicing (AS) modifications introducing such codons. NMD plays an
important regulatory role in brain neurons, but the in vivo dynamics of AS and NMD changes in neurological
diseases and under treatment were scarcely explored.
Results: Here, we report exon arrays analysis of leukocyte mRNA AS events prior to and following Deep Brain
Stimulation (DBS) neurosurgery, which efficiently improves the motor symptoms of Parkinson’s disease (PD), the
leading movement disorder, and is increasingly applied to treat other diseases. We also analyzed publicly available
exon array dataset of whole blood cells from mixed early and advanced PD patients. Our in-house exon array dataset
of leukocyte transcripts was derived from advanced PD patients’ pre- and post-DBS stimulation and matched healthy
control volunteers. The mixed cohort exhibited 146 AS changes in 136 transcripts compared to controls, including 9
NMD protein-level assessed events. In comparison, PD patients from our advanced cohort differed from healthy
controls by 319 AS events in 280 transcripts, assessed as inducing 27 protein-level NMD events. DBS stimulation
induced 254 AS events in 229 genes as compared to the pre-DBS state including 44 NMD inductions. A short, one
hour electrical stimulus cessation caused 234 AS changes in 125 genes compared to ON-stimulus state, 22 of these
were assessed for NMD. Functional analysis highlighted disease-induced DNA damage and inflammatory control and
its reversal under ON and OFF stimulus as well as alternative splicing in all the tested states.
Conclusions: The study findings indicate a potential role for NMD both in PD and following electrical brain
stimulation. Furthermore, our current observations entail future implications for developing therapies for PD, and for
interfering with the impaired molecular mechanisms that underlie PD and other neurodegenerative and neurological
disorders, as well as DBS-treatable conditions in general.
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NMD is an eukaryotic mRNA surveillance process that
detects, and selectively degrades, mRNA transcripts
which harbour premature termination codons (PTC;
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reproduction in any medium, provided the orproduce truncated proteins [2]. The complex NMD
mechanism is required to distinguish a normal stop
codon from a premature one, with both splicing and
translation crucial for this discrimination in mammals [3].
The pre-mRNA splicing machinery recognizes a ter-
mination codon as premature when it is located more
than about 50 nucleotides upstream of the final intron
position. Therefore, NMD can result from somatic DNA
rearrangements, the presence of upstream open reading
frames, the use of alternative open reading frames or
the presence of UGA codons [4-7]. More than a third of
reliably inferred Alternative Splicing (AS) events in humanstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tive usage of promoter and polyadenylation sites often
places a translation termination codon in a premature
context and thereby triggers NMD [9,10]. Thus, many
alternative mRNA isoforms carry PTCs that render them
as NMD targets and exhibit AS-induced NMD in humans
[11]. Examples include transcripts carrying an exon-exon
junction downstream of the stop codon, which induces
NMD by recruiting both splicing and translation termin-
ation factors. In some cases, AS can truncate the normal
protein product by causing a frame shift [12]. This may
simply remove a protein functional domain, or trigger
NMD if the new translation stop site is located too far
upstream from the original stop site [13]. Thus, AS
contributes to targeting mRNAs for NMD [14]. Also,
alternative polyadenylation sites may trigger NMD by
generating a long 3′-untranslated region (3′-UTR).
Notably, it is estimated that about 95% of the human
genes undergo AS changes which create numerous
transcript variants from a single gene [15]. This may
induce alternative C-or N-terminal sequences in the
produced protein, or lead to retained introns, alternative
coding of internal gene regions (i.e. exon inclusion or
exclusion) and may trigger NMD changes (Figure 1).
Correspondingly, mal-functioning NMD leads to mis-
regulation of a significant fraction of mRNAs [16]. For
example, the core small nuclear ribonucleoprotein (snRNP)
SmB/B′ self-regulates its expression by promoting the
inclusion of a highly conserved alternative exon in its
own pre-mRNA that targets the spliced transcript for
NMD [17]. While NMD factors are essential in early
embryonic development [18], the key physiological roles
of NMD are largely unknown.
That NMD functions as a quality control mechanism
tentatively suggested involvement of this particular RNA
surveillance process in both the initiation and progression
of neurodegenerative diseases and in treatment-induced
modifications of disease symptoms. Specifically, we
considered the rapid changes occurring following Deep
Brain Stimulation (DBS) treatment, a functional stereotac-
tic neurosurgery that is most commonly applied to ameli-
orate Parkinson’s disease (PD) motor symptoms through
targeting of the Sub-Thalamic Nucleus (STN) brain region
[19]. Following treatment, the normalized neuronal activity
then conveys rapid signals to peripheral tissues, such
that DBS improves the four cardinal PD motor symptoms:
tremor, rigidity, bradykinesia (“slow movement”), akinesia
(“lack of movements”) [20] and postural instability [20,21].
Overall, DBS has been shown to be particularly beneficial
for PD patients with severe motor complications [22] and
it has the unique advantage of reversibility and adjustability
over time [23]. In recent years, the use of DBS has rapidly
expanded both for other movement disorders and for
conditions such as treatment-refractory depression, epilepsyand psychiatric diseases, but the underlying molecular
mechanisms governing its effects remained unknown.
Although PD is a central nervous system disease, the
current estimation is that it initiates up to decades
prior to the appearance of the motor symptoms [24],
including autonomic nervous system involvement. The
spatio-temporal distribution pattern of PD-related inclu-
sions includes lesions in olfactory structures, projection
neurons and the enretic nervous system [25]. Moreover,
PD is also characterized by non-motor manifestations
[26]. In recent years, evidence for the presence of blood
RNA biomarkers for PD was accumulated from numerous,
independent studies [27-29]. Moreover, although PD symp-
toms reflect preferential neuronal death, DNA, RNA and
biochemical traits of the disease are detectable in blood
cells [30-32]. We [33] and others [34] have employed exon
arrays to identify genome-scale transcriptional [35] and
AS aberrations [33] in blood cells and leukocytes from
PD patients before and after DBS treatment (i.e. ON
stimulation) as compared with healthy control (HC)
volunteers and with patients with disconnected electrical
stimulation which lasted only one hour. The short elec-
trical stimulation cessation rapidly re-induces the disease
motor symptoms, suggesting involvement of fast brain-
to-body communications. Most recently, we have managed
to classify brain transcriptomes of an external cohort of
PD patients from control samples based on AS signatures
detected in our cohort of PD patients’ blood leukocytes
and matched HC [36]. Leukocytes, in contrast to whole
blood cells, can also report or respond to brain infarction,
for example in stroke [37].
In our current study, we zoomed in to profile NMD
events in leukocyte transcripts from PD patients before
and after DBS neurosurgery and under disconnected
electrical current, aiming to challenge the hypothesis
that NMD may be actively involved in the impaired
brain-to-body signalling processes that accompany PD
and in the correction of such impairments under DBS
which mitigates PD symptoms. We predicted NMD profile
changes in PD leukocytes compared to healthy volunteers
and in post-DBS compared to pre-DBS preparations,
and surmised that disconnecting the electrical stimulus
would again alter the NMD profile. To challenge these
predictions, we integrated a web-available exon array
data set of human PD blood samples [34] with our own
PD blood leukocyte exon array datasets of patients pre-
and post-DBS and characterized the corresponding
NMD events. Here, we provide evidence for NMD pro-
file changes that are compatible with a regulatory role
of NMD in both PD and under DBS ON Stimula-
tion as well as following an hour stimulation cessation
(i.e. OFF stimulation). To our knowledge, this is the
first evidence that electrical stimulation in the brain












Figure 1 Types of protein-level functional implications of interrogated AS events. The AS events detected in both whole blood and
leukocyte exon array data sets of PD patients and healthy control (HC) volunteers, and pre- and post- DBS treatment, included alternative N and
C termini, retained introns, alternative coding of internal gene regions, NMD and truncation (>50% reduction in protein product size). Top: a
schematic structure of a gene. Grey: introns, color coded regions: exons. Direction: from 5’ to 3’ UTR. PTC: Pre-Termination codon. Below it, the
structure of a full transcript is given, with a theoretical protein product structure.
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for reversal.
Results
AS events in blood mRNA from mixed early and advanced
PD patients induce a small number of NMD events
To characterize alternative splicing changes in exon array
datasets from PD patients, we first studied our in-house
exon array leukocyte dataset (of overall 27 samples) by
measuring the exon level splicing index and assessing
functional protein-level implications of these measures in
our data-set, as well as in an additional independent exon
array dataset of whole mRNA extracted from blood samples
of mixed early and advanced PD patients and healthy
control volunteers (overall 28 samples) [34]. Exon level
splicing-index (SI) analysis of the mixed published cohort
interrogated 27,305 transcripts, yielded 146 AS events
(defined as presenting either SI or MiDAS p-value < 0.05
and at least 2-fold change) that occurred in 136 genes
(Figure 2Ai and Additional file 1: Table S1). Overall, 217functional changes were predicted in the corresponding
protein products for the detected AS transcripts, the most
abundant of which were altered N- and C- termini
(together comprising 77% of all changes, Figure 2Aii).
Of these, a total of 9 AS changes were predicted to
induce NMD protein-level changes in patients compared
to controls (Additional file 1: Table S1). On average, 67% of
the events were associated with more than one functional
event, and alternative N- terminus showed the largest
overlap with other functional predictions (Figure 2Aiii).
The detected genes included the kinesin family member 1
binding protein KIAA1279, previously identified as related
to cortical brain malformations [38]. One of the mixed
cohort detected genes, RPL10 also showed general gene
level expression change detected previously by transcript-
level analysis of our advanced PD patient’s cohort exon
array data [35]. Functional enrichment analysis of the AS
genes detected as changed in the mixed cohort identified
ATP binding, alternative splicing and transition metal ion
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Figure 2 Post-DBS increases in AS-induced NMD events. A-D: Shown are total numbers of AS events (i), relative frequency of AS events in
exons (ii), and overlapping ratio between functional predictions of the changed exons (black denotes no overlap) (iii) that were detected by exon.
Exon level analysis of exon array data from (A) whole blood from mixed early-advanced PD patients external cohort and HC volunteers (B)
advanced PD patients as compared with control volunteers (C) advanced patients post-DBS on stimulation (PD Stim-ON) as compared with
pre-DBS and (D) post-DBS OFF stimulus as compared with one hour earlier ON- stimulus. (E): Total numbers of NMD and truncation AS events
detected in each of the tested conditions. Purple: truncation events, orange: NMD, green: both. The NMD events are a subset of the total number
of detected AS events that were observed in all of the interrogated microarray probe-sets.
Soreq et al. BMC Genomics 2013, 14:478 Page 4 of 14
http://www.biomedcentral.com/1471-2164/14/478
Table 1 High enrichment for alternative splicing pre- and post-DBS on and off stimulation
Type Category Term Count % p-value
PD SP_PIR_KEYWORDS cytoplasm 72 2.875 0.000
GOTERM_CC_FAT GO:0043232 ~ intracellular non-membrane-bounded organelle 57 2.205 0.000
SP_PIR_KEYWORDS phosphoprotein 128 4.952 0.000
GOTERM_CC_FAT GO:0005819 ~ spindle 11 0.426 0.000
SP_PIR_KEYWORDS alternative splicing 129 4.990 0.000
UP_SEQ_FEATURE splice variant 129 4.990 0.000
GOTERM_CC_FAT GO:0015630 ~microtubule cytoskeleton 20 0.774 0.000
GOTERM_CC_FAT GO:0005856 ~ cytoskeleton 35 1.354 0.000
GOTERM_CC_FAT GO:0044430 ~ cytoskeletal part 26 1.006 0.000
GOTERM_CC_FAT GO:0031974 ~membrane-enclosed lumen 40 1.547 0.001
GOTERM_BP_FAT GO:0033554 ~ cellular response to stress 19 0.735 0.001
SP_PIR_KEYWORDS cytoskeleton 20 0.774 0.001
SP_PIR_KEYWORDS atp-binding 31 1.199 0.002
GOTERM_MF_FAT GO:0004674 ~ protein serine/threonine kinase activity 15 0.580 0.003
GOTERM_BP_FAT GO:0006259 ~ DNA metabolic process 16 0.619 0.003
GOTERM_CC_FAT GO:0070013 ~ intracellular organelle lumen 36 1.393 0.003
GOTERM_BP_FAT GO:0032092 ~ positive regulation of protein binding 3 0.116 0.004
GOTERM_CC_FAT GO:0005815 ~microtubule organizing center 10 0.387 0.004
GOTERM_MF_FAT GO:0000166 ~ nucleotide binding 46 1.779 0.005
GOTERM_CC_FAT GO: 0005694 ~ chromosome 14 0.542 0.005
GOTERM_CC_FAT GO:0043233 ~ organelle lumen 36 1.393 0.005
SP_PIR_KEYWORDS acetylation 50 1.934 0.005
GOTERM_CC_FAT GO:0070161 ~ anchoring junction 8 0.309 0.006
GOTERM_MF_FAT GO:0005524 ~ ATP binding 33 1.277 0.006
SP_PIR_KEYWORDS nucleotide-binding 35 1.354 0.006
GOTERM_CC_FAT GO:0005813 ~ centrosome 9 0.348 0.007
GOTERM_MF_FAT GO:0032559 ~ adenyl ribonucleotide binding 33 1.277 0.008
SP_PIR_KEYWORDS transferase 30 1.161 0.008
GOTERM_BP_FAT GO:0030099 ~myeloid cell differentiation 6 2.232 0.008
GOTERM_BP_FAT GO:0009057 ~macromolecule catabolic process 20 0.774 0.008
GOTERM_CC_FAT GO:0019898 ~ extrinsic to membrane 14 0.542 0.009
GOTERM_MF_FAT GO:0030554 ~ adenyl nucleotide binding 34 1.315 0.009
DBS UP_SEQ_FEATURE FEATURE splice variant 115 53.488 0.000
SP_PIR_KEYWORDS phosphoprotein 112 52.093 0.000
SP_PIR_KEYWORDS alternative splicing 114 53.023 0.000
UP_SEQ_FEATURE domain:EH 1 3 1.395 0.002
UP_SEQ_FEATURE domain:EH 2 3 1.395 0.002
GOTERM_CC_FAT GO:0005829 ~ cytosol 25 11.628 0.007
OFF SP_PIR_KEYWORDS alternative splicing 63 55.263 0.000
UP_SEQ_FEATURE splice variant 61 53.509 0.001
The functional terms as well as sequence feature and domains detected as the highest enriched in spliced transcripts of leukocyte RNA extracted from blood
samples of advanced PD patients’ pre-DBS and post-DBS ON- and following one hour OFF- stimulus (p < 0.01) are shown. Red: the repeatedly appearing term
alternative splicing. Given are: the compared state (PD: patients pre-DBS compared with control volunteers, DBS: PD patients post-DBS on electrical stimulation as
compared with pre-DBS state, OFF: PD patients post-DBS following one hour of electrical stimulation cessation. Category: the type of term, term: the name of the
term (and Gene Ontology – GO- ID for GO terms), count: the number of spliced transcripts that are associated with the corresponding term, %: the percent of the
spliced transcripts in the term, p-value: statistical significance.
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compared with healthy controls
Our dataset differed from the published one in two
principal points: both the clinical characteristics of
recruited patients (advanced stage as compared to mixed
composition) and the population of blood cells from which
RNA was extracted (purified leukocytes as compared to
the total variety of blood cells). Overall, 319 AS events
were detected in the advanced patients compared to
control volunteers (Figure 2Bi). These included 175
inclusion and 144 exclusion events, which totally occurred
in 280 genes (Additional file 3: Table S3). These spanned
the innate immunity gene FBXO9 [39] and LRRC8C,
which we identified as a PD leukocyte signature gene,
based on its transcript level changes [35]. Five spliced
transcripts were identified both in this mixed cohort and
in our advanced PD patients’ blood leukocytes: BTNL8,
RAD17, ARL17B, UTY and DROSHA (suggesting possible
relevance of microRNA regulation of the detected changes).
Of the detected AS changes, 284 were predicted to cause
functional change at the protein level (i.e. alternative N-
or C- termini, NMD, truncation, change of alternative
coding regions and intron retention). The majority of
those were alternative C-termini (41%) and N-termini
(35%) (Figure 2Bii and Additional file 3: Table S3). On
average, 63% of the identified AS events predictably
induce more than one functional change (Figure 2Biii),
with 28 predicted to induce NMD (Figure 2Bii, E). Notably,
in spite of the more heterogeneous cell composition
and the mixed early-late PD patients in the whole
blood cohort, our exon array leukocyte dataset yielded
similar proportions of the functional prediction groups to
those of the mixed patient’s cohort: 37% and 38% terminal
changes and 11% retained introns (compare Figure 2Bii
to Figure 2Aii) with more than one functional change
following each event.
Functional analysis of the PD AS-modified transcripts
using EASE [40] identified the term alternative splicing
as having the largest number of assigned genes (i.e. 129)
in the advanced patients (p < 0.01 under Table 1, and
p < 0.05 under Additional file 4: Table S4), compatible
with many of the spliceosome components being subject
to self-AS changes [41]. Notably, the advanced cohort
presented 1% alternative coding events, considerably less
than the 6% observed in mixed patients (as compared
with the corresponding matched control volunteers of
each tested cohort). In contrast, the fractions of NMD
events were similar to the advanced and mixed cohort
(5% compared to 4%). Furthermore, the total number
of NMD functional predictions was 3-fold larger in the
advanced patients (28 compared to 9), possibly reflecting
increased NMD effects and decreased variability of
blood cell protein composition in purified leuko-
cytes and with disease progression. Thus, NMDevents showed an apparent association with the severity
of PD.
We have further challenged these observations using
the robust FIRMA analysis approach [42]. While in the
SI approach, the signal of each exon is normalized by
dividing it by the measured gene expression level, the
FIRMA approach models the expected behaviour of each
exon by calculating its deviation from a robust estimate
of the gene expression level. This analysis yielded 167
AS events that occurred in 120 genes overall (Additional
file 5: Table S5) in advanced PD patients compared to
controls, with 8 of them identified as NMD changes. For
example, the vacuolar protein VPS37A gene was detected
as both AS- and NMD-changed. Other examples are the
phosphodiesterase PDE7A1/3, inhibition of which rescues
dopaminergic neurons in cellular and rodent models of
PD [43] and the trans-ketolase enzyme TKTL1 [35],
which also showed PD association in a gene level analysis
of the same cohorts [35]. 29 additional events involved
truncation, occurring in non-NMD genes and included
five of the 29 PD signature genes that we previously
identified in this same cohort: the B cell development
controller LRRC8C, the solute carrier protein SLC6A8,
the ATPase ATP11B, the cell division cycle protein
CDC20 and TKTL1 [35]. Two genes showed both fold-
change and modified AS: the tumorigenic keratin KRT7
[44] and the oncogene MED29 [44]. Functional analysis
revealed that the FIRMA-detected genes were highly
enriched with alternative splicing.
Although there was no overlap between the specific
genes identified by the SI and the FIRMA analysis
methods, we noted that there was an overlap in terms of
gene families between the two lists. For example, the
solute carrier (SLC) as well as zinc finger and WD repeat
domain-containing genes were detected as significantly
changed by both methods. Notably, there was also an
overlap between the functional enriched terms of the SI
and FIRMA detected genes, for example – alternative
splicing, with the SwissProt keyword phosphoprotein as
the top detected functional enriched term in both lists,
found in 69 of the SI, and 70 of the FIRMA detected
genes. The biological process protein transport also
appeared as significantly enriched in both lists.
DBS stimulation-induced AS changes in PD patients
leukocytes predicted to yield NMD
Next, we addressed the question of whether the observed
splicing changes are correlated with treatment efficacy. We
have conduced exon-level SI analysis of blood leukocyte
transcripts from PD patients post-DBS, upon symptoms
stabilization, and under electrical stimulation (PD-Stim-ON)
as compared with one day prior to DBS neurosurgery
(patients clinical information is described under [35]).
While PD patients showed 319 AS events compared to
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(Figure 2Ci and Additional file 6: Table S6), 44 of which
were predicted to induce NMD at the protein level. Thus,
although the total number of overall AS events was
smaller post- as compared with pre-DBS, the fraction of
NMD ones was higher (Additional file 6: Table S6 and
Figure 2 C, E), demonstrating considerable DBS-inducible
transcript destruction in post-DBS leukocytes. Examples
included the erythrocyte membrane protein EPB41L4A
with DBS-induced inclusion of an alternative N-terminus,
the inflammatory response gene A2M [45], the splicing
factor SRRM1 and the I- kB kinase cascade regulator
IKBKE. 31 of the identified transcripts were predicted to
undergo truncation following the splice changes, of these
9 were also predicted to undergo NMD change. Overall,
80% of the transcripts exhibited more than one splicing
event. The functional protein-level implication of the
DBS-induced AS changes at the protein level was overall
similar to those observed both in advanced and in mixed
PD patients pre-DBS as compared with healthy control
volunteers (Figure 2Cii, Ciii). The post-DBS NMD predicted
transcripts largely differed from the disease-predicted
NMD transcripts, with only 3 genes predicted to undergo
AS induced NMD changes in both the patients’ leukocytes
pre-DBS compared to controls and in the post-DBS
stimulated state. Functional sequence and feature enrich-
ment analysis of the detected DBS-modified transcripts
revealed enrichment in the following terms: alternative
splicing, inflammatory response, metal and zinc ion
binding, regulation of cellular response to stress and
apoptosis (Table 1 and Additional file 7: Table S7).
Functional enrichment analysis of only the NMD predicted
transcripts detected alternative splicing, DNA repair and
regulation of protein kinase cascade as highly enriched.
Of the DBS-modifiable AS transcripts, 23 were also
detected in the PD patients pre-DBS and 2 of those
showed DBS-inducible NMD change: the TATA Box
gene TAF1D (with inclusion of exon E9-7) and VDAC3,
where inclusion of exon E5-1 was predicted to affect
functional NMD decay. Four of the DBS-induced AS
genes also showed expression change in the same patients:
the tumorigenic protein TPRG1, the keratin KRT7, the
vesicular trafficking protein EXOC7 and the NMD factor
UPF3A, which also changed in patients compared with
controls. The treatment-induced AS genes also included
interleukin (IL) 19, suggesting immune and NMD relevance
to the DBS-induced improvement of motor functions.
Although inducing less exon level AS changes as compared
with PD, DBS increased the diversity of the detected events
to 631 functional predictions (with 40% of the events
predictably inducing more than one transcript change,
on average). FIRMA analysis of the post-DBS ON- stimu-
lus state as compared with the pre-DBS state detected 110
AS events in 106 transcripts (Additional file 8: Table S8),and 8 of these were also identified by the SI method as
subjected to DBS-induced AS changes. FIRMA also
identified two genes exhibiting NMD change: the enzyme
PCBD2 with post-DBS inclusion of exon 2, and the
apoptosis-inducing factor EAF2 that exhibited post-DBS
inclusion of exon E10.1.
The DBS-induced NMD/AS changes are rapidly modifiable
and electrical stimulation-dependent
The DBS-induced changes in NMD/AS could potentially
be due to the operation procedure, the reduced drug dose
and/or the electrical stimulation itself or all of these
together. To test these possibilities, we further examined
blood leukocytes RNA of the DBS-treated patients follow-
ing one hour off electrical stimulation (Stim-OFF). We
noted 133 AS changes within only one hour following
disconnection of the stimulus (Figure 2Di and Additional
file 9: Table S9), further decreasing the diversity of the
changes to 373 functional predictions (such that every
third AS change would predictably modify the protein
product of the modified transcript). Functional enrichment
analysis once again detected alternative splicing as the top
enriched term (Table 1, red color and Additional file 10:
Table S10). Of the detected exons, 21 were also identified
as undergoing AS changes in the treatment-affected genes
(i.e. in DBS stimulation ON-stimulus as compared with
the pre-DBS state). Of these, we observed C-terminal
PD-related AS changes and DBS-induced NMD changes
in the serine protease CORIN, the carbonic anhydrase
CA1, the cell division controller TMEM67 and the
hematopoietic Krueppel-like factor KLF8. Other detected
genes, such as the glycogen phosphorylase PYGM, showed
OFF-stimulus dependent expression change.
At the level of functional implications, the fractions of
alternative N- and C-termini out of the total functional
predictions were comparable with those observed in
the ON-stimulus state (36/36% OFF and 37/38%, ON)
(Figure 2Dii and Cii, peach and red colors). However, the
fractions of truncated transcripts increased OFF stimulation
as compared to both pre- and post-ON states (8% as
compared with 4% and 5.7%). Also, the fractions of retained
introns were similar pre- and post-DBS (11%) but increased
upon stimulation cessation (to 13%). In contrast, NMD
events declined to 6.2% of the total events as compared
with post-DBS on stimulation (Figure 2E), reinforcing the
indication that the NMD changes depended on the stimu-
lus. FIRMA comparison of the OFF- and ON-stimulus
states, only one hour earlier detected 55 AS events in 55
transcripts (Additional file 11: Table S11). Of the FIRMA
detected genes, seven were also detected in the OFF- as
compared with the ON-stimulus state through SI analysis,
including the fibroblast growth factor receptor FGFR1 [46].
That the DBS-induced capacity to cause NMD/AS changes
was largely lost under OFF-stimulus conditions (Figure 2E)
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itself rather than the operation or the modified drug dose.
To further challenge the power of the observed differ-
ences, we performed hierarchical classification analysis
on all of those AS regions that were implicated to cause
NMD in the mixed patients’ cohort, and found correct
classification of all samples except for 2 misclassifica-
tions (Figure 3A). In comparison, directly classifying the
expression levels of the regions that exhibited NMD
changes correctly distinguished all of our advanced PD





Figure 3 AS-induced NMD predictions segregate patients from controls
early-advanced PD whole blood samples by SI values of the changed exon p
seventeen patients were mis-classified with the HC group. (B) Classification of
index (SI) values of those AS exons predicted to induce NMD in blood leukoc
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compared to pre-DBS state based on their expression
levels (Figure 3C, PD and PD Stim-On). Finally, the
AS probe-sets predicted to be subjected to NMD suc-
cessfully classified the samples OFF-stimulus from the
one hour earlier ON- stimulus state based on their
expression levels (Figure 3D, PD Stim-On and PD
Stim-Off). Thus, NMD changes emerged as a principal
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and post-treatment states. (A) Hierarchical classification of mixed
robe sets predicted to induce NMD change. Note that seven of the
advanced PD patients’ pre-DBS from matched HC based on the splicing-
yte samples. (C) HCL classification of patients’ post-DBS ON- stimulus and
the SI values of the AS/NMD detections in the Stim-On state. Right: one
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disease progression and under DBS
Post-hoc functional enrichment analysis of the AS genes
detected in the mixed published PD cohort revealed
enrichment in nucleotide-binding, metal-binding, Natural
killer cell mediated cytotoxicity, ATP-binding, transition
metal ion binding, ATP binding, gene silencing and positive
regulation of immune response (Additional file 2: Table S2).
In our advanced PD cohort as compared with age and
gender matched healthy control volunteers (HC), post-hoc
GO and protein domains enrichment functional analysis
[40,47] of the AS modified transcripts likewise detected
enrichment for the Molecular Function (MF) term ATP
binding and the Biological Processes (BP) terms metal ion
transport, in addition to mitochondrion organization
(Table 1 and Additional file 2: Table S2), both of which
also emerged as PD-relevant in brain transcriptomes from
mouse PD models [48]. The AS-modified genes further
included the PD-related ubiquitin ligase component FBXO9
[49] which exhibited inclusion of an N-terminal exon in
PD leukocytes. Functional analysis of only AS transcripts
predicted to cause NMD functional change detected
significant enrichment in the cell cycle checkpoint GO
term (Table 1).
The genes that underwent AS change following DBS
revealed the highest enrichment in splice variant sequence
feature (which appeared in 28 of the NMD predicted
genes), the Swissprot database term alternative splicing
(Table 1 and Additional file 7: Table S7), and the GO BP
terms alternative splicing, oxidative phosphorylation,
mitosis, protein transport, leukocyte proliferation and
ATP-binding. Those genes that presented AS-induced
NMD functional prediction following DBS exhibited
enrichment in regulation of protein kinase cascade, cellular
response to stress, alternative splicing, DNA damage,
DNA repair and disease mutation (Table 1, lower panel).
Highlighting the role of NMD in the DBS-inducible
leukocyte AS changes, the GO BP term nuclear-transcribed
mRNA catabolic process, nonsense-mediated (NMD) decay
was also enriched in the group of treatment-increased AS
events.
Comparing post-DBS leukocyte exon expression of
the OFF- to the one hour earlier ON-Stimulation state
highlighted 63 and 61 genes of the alternative splicing
and sequence feature splice variant terms, with metal
ion-binding site: Magnesium 2 as the top sequence feature
detected. Additional enriched pathways included comple-
ment alternate pathway activation (hinting at immune
involvement under OFF- state), acute inflammatory re-
sponse and mitochondrion (Additional file 10: Table S10).
Narrowing of the functional enrichment analysis to only
the NMD fraction of the detected AS transcripts detected
enrichment in alternative splicing, highlighting the rapid,
NMD-linked, molecular signature reversal of stimulationtreatment following the one hour OFF stimulus. Thus,
while the different interrogated states showed variable
enrichment features, all shared AS-related elements as
primarily affected.
Discussion
Despite its biological importance, the functional and
dynamic implications of NMD changes as well as the
link between splicing and functional NMD implications
were never tested in human patients. Overall, an inclusion
or exclusion of a single probe set often reflect more than
one functional change; and those events that modified
N- and C- termini were frequently accompanied in our
datasets by functional NMD prediction. Specifically, in
PD patients’ blood cells and leukocytes pre- and post-DBS,
ON- and OFF- stimulus, we identified AS changes that
predictably induce NMD, modify N- and C- termini,
retain introns, alter coding events (defined as a change in
internal, rather than terminal protein sequence) and cause
truncation (a splicing event that causes a reduction of at
least 50% in the protein product size (Figure 1), or induce
various combinations of those changes. We detected more
events in advanced PD patients’ leukocytes than in whole
blood cells from the mixed independent cohort, with
further increases following DBS stimulation and rapid
decreases under OFF-stimulus. The fraction of leukocyte
NMD events increased from 5.3% pre-DBS to 7% post-
DBS and declined again upon stimulation cessation to
6.2%. Moreover, the number of NMD causing events was
higher post-DBS as compared with both pre- and post-
OFF states as well as the mixed cohort of early-late PD,
and the observed AS changes OFF- stimulus that were
accompanied by returning tremor symptoms also wiped
off much of the DBS-mediated AS changes in leukocyte
mRNA. A comparison of purified leukocyte RNA from
advanced patients to the whole blood preparation from
the published mixed cohort revealed that both the splicing
and NMD implications were massive in leukocytes from
advanced patients as compared with mixed early and
advanced whole blood cells. Together, these findings
reflect progressive NMD increases with disease progression
and treatment-induced changes, dependent on the elec-
trical stimulus; and suggest that the NMD process is one
of those checks and balances mechanisms regulating RNA
metabolism under modified brain-to-body signalling.
One common outcome of AS events is suppressed
function of a gene by the production of non-functional
transcripts, which can be achieved through the NMD
mechanism [50-53]. NMD was first identified in the late
1970’s in thalassemic carriers of nonsense globin mutations
as the cause for decreased abundance of affected mRNA
transcripts, rather than production of truncated proteins
[54]. Recently it was discovered that NMD also regulates
normal gene expression [55], together suggesting that
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gain- of -function changes and be of clinical benefit.
AS/NMD coupling was suggested before [56] and was
termed ‘regulated unproductive splicing and translation’
(RUST) [11,50,57]. Correspondingly, the identified NMD/
AS changes reflect DBS-inducible enhancement of cellular
response to stress and alternative splicing, both were
rapidly modified by stimulation cessation to NMD-induced
functional changes in immune and inflammation proper-
ties. We observed DBS-stimulus NMD predictions in genes
participating in DNA damage and repair and alternative
splicing, compatible with our findings of bidirectional
risk-protection role of these pathways by meta-analysis
of mouse PD model brain transcriptomes [48]. Overall,
this study expands our observations for disease-related
AS changes in both brain and blood cells. To the best of
our knowledge, this is the first demonstration of splicing-
mediated NMD irregularities under disease and of their
correction through DBS-related brain-to-body messages,
changing transcript profiling in blood leukocytes as a
symptoms-related mechanism of action.
PD prevalence (0.5-1% from 65–69 years, 1-3% over
80 years [58] and 4-5% over 85 [20]) is predicted to grow
worldwide within the next decades [59], highlighting the
importance of developing new therapeutic strategies which
should ideally target the disease-related impairments. In
this context, 50% of known disease-associated mutations
in RNA-binding proteins cause nervous system diseases
[60,61]. Examples include SMN2 mutations, which induce
motor neuron degeneration in spinal muscular atrophy
[62,63], and mutations in the RNA-binding proteins TDP-
43 and FUS, which induce amyotrophic lateral sclerosis
[64-66]. Also, neuron-specific splicing factors such as
NOVA regulate transcript categories that are essential
for neuronal functioning [67], and transcriptome profiling
demonstrates altered brain AS events in various engineered
mouse models of human degenerative diseases, PD among
them [63,68,69]. Thus, global changes in AS regulation
may contribute to the initiation and/or progression of
neurodegenerative processes. Therefore, searching for
PD-related mechanism(s) related to RNA metabolism is
called for. In this context, NMD has a role in preventing
dominant diseases and can also eliminate mRNAs that
would otherwise result in the production of partly or fully
functional truncated proteins. In such instances, interven-
tions to prevent degradation of transcripts containing
PTCs may be therapeutically useful. Approaches to
protect mRNAs containing a PTC from NMD, thereby
promoting the synthesis of a functional protein, have
been explored for cystic fibrosis, Duchenne muscular
dystrophy, Hurler syndrome and X-linked nephrogenic
diabetes insipidus [3]. Modulation of either the PTC of
the disease-associated AS transcripts, or of those genes
regulating the NMD process, through RNA interference,may enable the development of NMD-targeted therapeu-
tics in the future.
DBS is increasingly used for other human diseases
including depression [70] and chronic pain [71] where it
is predicted to serve for treating tens of thousands of
people in the world during the next decade. In addition
to its established use for treating the deliberating motor
symptoms of PD [72], DBS has also been proven to be
a powerful tool for alleviating the symptoms of the
treatment-resistant motor diseases essential tremor
[73] and dystonia [74]. Additionally, DBS of a variety
of brain regions is being increasingly tested to treat a
growing number of non-motor diseases including behav-
ioural ones. These include obsessive-compulsive disorder
(OCD), major depression [75] and Tourette syndrome
[76]. However, the mechanism of action of DBS therapeu-
tics is still obscure. Our current study opens new venues to
exploring the molecular mechanisms by which DBS affects
motor and cognitive symptoms of both PD and other
neurological disorders.
Conclusions
We identified dynamic changes of AS-induced NMD
assessed events in PD patients’ blood cells and following
deep brain electrical stimulation. Specifically, we noted
that both the disease and yet more so, the DBS treatment
induced NMD prediction increase with disease-relevant
functional implications as compared with both healthy
control volunteers and the pre-surgery state. Intriguingly,
those NMD events that were identified in the mixed
cohort of early and advanced patients were reminiscent of
those in the advanced cases, albeit less discriminating. A
surprisingly rapid decline in both AS and NMD events
occurred following an hour OFF-stimulus, and Alternative
Splicing changes emerged as a commonly modified func-
tion in all tested stages, with known PD-related pathways
identified as enriched in AS-induced NMD changes
(Figure 4). Zooming into NMD events showed classification
between advanced PD patients and controls, an inverse
pattern of changed NMD events following DBS and reversal
of that pattern in OFF-stimulus samples. DBS is rapidly
emerging as a promising therapy for various neuronal
disorders and is increasingly applied for treating move-
ment disorders (PD, dystonia and essential tremor), and
increasingly tested to treat other diseases such as epilepsy
and major depression. DBS may become in the future tai-
lored and patient-specific, utilizing specific target regions
for individual clinical manifestations. The findings of this
study may therefore have future implications for exploring
and interfering with the impaired molecular mechanisms
that underlie not only neurodegenerative and neurological
disorders but also other DBS-treatable conditions. In
particular, our findings are relevant for searching for novel
PD-targeted therapeutics.
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Figure 4 Post-DBS NMD spliced transcripts correct disease
pathways. (A) PD patients’ pre-DBS exhibited functional changes of
AS genes enriched in immune system development, ATP-binding,
mitochondrion organization, alternative splicing and metal ion transport.
NMD/AS genes were enriched in cell cycle checkpoint process. (B) DBS
treatment induced functional changes in leukocyte proliferation, ATP-
binding, Oxidative phosphorylation, protein transport, mitochondrion
outer membrane, alternative splicing, metal ion transport and mitosis.
(C) DBS-induced NMD/AS functional enrichment included regulation of
protein kinase cascade, cellular response to stress, alternative splicing, DNA
damage, DNA repair and disease mutation.
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This study was authorized and approved by the Ethics com-
mittee of the human review board (Hadassah University
Hospital, Ein-Kerem, approval number 6–07.09.07) in
accordance with the Declaration of Helsinki principles.Following oral agreement, all participants signed informed
consent prior to inclusion. The decisions regarding the
DBS treatment were taken solely by physicians at the
Hadassah Ein Kerem Hospital and the PD patient volunteers
were only subsequently recruited for the study.
Independent PD whole blood microarray cohort
28 exon array raw CEL files of whole blood mRNA from
17 mixed early and late PD patients (time from diagnosis:
2–23 years) and 11 healthy control volunteers (HC) [34]
were obtained from the Gene Expression Omnibus (GEO)
database.
Patient and controls recruitment, DBS neurosurgery and
clinical evaluation
Seven PD male patients nominated for bilateral DBS neuro-
surgery were recruited to the study and six healthy age-
matched male controls (HC). Subjects were assessed for
their clinical background and state and fulfilled detailed
medical history questionnaires. Patients with other medical
conditions were excluded, including depression and past
and current DSM Axis I and II psychological disorders
(SM), chronic inflammatory diseases, coagulation irregu-
larities, previous malignancies or cardiac events, or any
other surgical procedure up to 1 year pre-DBS. Exceptions
were hyperlipidemia (present in two patients and three
control volunteers), hypertension and diabetes (two patients
each). All patients went through bilateral STN-DBS
electrode implantation (Medtronics, USA) and were under
dopamine replacement therapy (DRT) both pre- and post-
DBS, with a significantly reduced dosage post-DBS (t-test
p < 0.01). The last medication was administrated at least
5 hours pre-sampling. The patients and healthy volunteers
also exhibited similar total white and red blood cell
counts. Further clinical details (such as age, disease
duration and DRT dosage) are given under the supporting
information of [77]. Blood samples were collected from
each patient at three time points: (1) one day pre-DBS
upon hospitalization, with medication (2) post-DBS ON-
stimulus (range 6 – 18 weeks) (Stim-ON), when reaching
optimal clinical state as evaluated by a neurologist and
under a lower therapy dose, and (3) OFF-stimulus, follow-
ing 60 minutes OFF electrical stimulation (counted from
stage 2) (Stim-OFF). Healthy control volunteer samples
were collected from six age- and gender-matched academic
staff researchers at the Edmond Safra campus of the
Hebrew University of Jerusalem. Blood sample collection,
RNA extraction and microarray sample preparation,
hybridization and scanning were all as detailed [27].
Probe-set summation
Microarray probe-set summation of the input CEL files
was conducted using Affymetrix Power Tools (APT)
through AltAnalyze.
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Splicing targeted analysis of both sets of exon array data
was conducted using the software AltAnalyze using the
Ensembl human database (#37) (http://www.ensembl.
org). Briefly, AS targeted analysis was conducted using
both Splicing-Index (SI) [78,79] and Finding Isoforms
using Robust Multichip Analysis (RMA) linear model fitting
[42]. Prior to the analysis, probe-sets with detection above
background (DABG) p-value were removed from the input
data. Overall, following the filtering, 487,571 core probe sets
remained in our in house data set for analysis and 238,749
in the independent data set. Expression data was formatted
to log scale. The SI is derived by subtracting the group-
normalized intensity of the patient group pre-DBS from
control samples or from post-ON state or post-ON
from post-OFF states. The SI represents the ratio of the
exon intensities between the two tested conditions fol-
lowing normalization to the gene intensities and serves
to measure the exon inclusion level. The SI value is
calculated as follows: the gene-level normalized probe-set
intensity is defined as NI ¼ probeset intensitygenej level intensity for the j-th gene
and the splicing-index value subsequently calculated as
SI ¼ log2 NIpsiNIpsi
 
ps_i: the i-th probe set intensity of the
j-th gene. All calculated SI values were normalized using
the NI equation to the constitutive gene expression
level. AS change was detected using one-way ANOVA
(equivalent to t-test) in order to probe for differential
inclusion of exons into genes. In the case of post- compared
to pre-DBS and OFF compared to ON stimulation analyses,
a paired t-test was conducted. The significance of micro-
array pair-wise comparisons was derived by 2-tailed t-test
on the SI calculated values. To detect the highest propor-
tion of true positives the analyses included only the
following: (1) probe sets with Detection Above Background
(DABG) p-value > 0.05 (2) exons with a gene level
normalized log ratio between experimental conditions > 2,
(3) t-test p-values < 0.05 (4) FDR p-value < 0.05 (5) maximal
absolute gene expression change = 3 and (6) core level
probe sets. The Ensemble database served, through
AltAnalyze, to map each alternative splicing event to the
corresponding functional prediction (e.g. NMD) either dir-
ectly or through comparison of all transcripts for that gene.Pathway analysis
Pathway post-hoc analysis on the detected AS transcripts
was conducted through the DAVID [80,81] EASE [40]
functional enrichment analysis module. The identified
biological themes included Gene Ontology (GO) [82]
terms, KEGG pathways [83], Swissprot (SP) [84] sequence
features and Protein Information Resource keywords
(SP-PIR), the InterPro protein families database [85]
and the BioCarta DataBase (http://www.biocarta.com/).Availability of supporting data
The data-sets supporting the results of this article are avail-
able in the GEO repository, http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE23676 and http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE18838.Additional files
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